{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053553","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.331340+00:00","generated_at":"2026-06-02T21:42:35.584987+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance","bullets":["LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).","Gross margin expands to 70% from 59% on favorable mix and lower production costs.","Net loss narrows to $9.1M ($0.25/share) from $13.2M ($0.42); adjusted loss $4.4M ($0.12).","Raises FY2024 revenue guidance to $132-137M (from $128-135M) and gross margin to 68-70%.","Cash remains strong at $125.4M, down slightly from $127.2M at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053553","json":"https://secwatch.observer/filing/0000950170-24-053553.json","markdown":"https://secwatch.observer/filing/0000950170-24-053553.md","text":"https://secwatch.observer/filing/0000950170-24-053553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024053553/0000950170-24-053553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024053553/rxst-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:42:35.584987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"956b462a9eb842287ebd2554baaf9f5b4e3d4cd4","claim":"RxSight, Inc. reported the three months ended March 31, 2024 results: revenue $29.5 million, net income $(9.1) million, EPS $(0.25) per basic and diluted share. Guidance raised.","evidence_excerpt":"following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights • Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: • The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+TM), representing a 92% increase in procedure volume","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024053553/0000950170-24-053553-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$29.5 million"},{"label":"Net income","value":"$(9.1) million"},{"label":"EPS","value":"$(0.25) per basic and diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}